PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35114569-4	2022	Overexpression of BCL2A1 attenuated the sensitivity to quizartinib, a type II TKI, and venetoclax, a selective BCL2 inhibitor, in AML cell lines.	quizartinib	55-66	B cell leukemia/lymphoma 2 related protein A1a	Mus musculus	18-24